Axsome Therapeutics, Inc. Announces 2026 Annual Stockholder Meeting Results
Key Highlights from the 2026 Annual Meeting
- Date of Meeting: June 5, 2026
- Location: Axsome Therapeutics, Inc., One World Trade Center, 29th Floor, New York, NY 10007
- Quorum Achieved: Approximately 85.1% of eligible shares were represented, with 43,777,536 out of 51,439,952 shares present in person or by proxy.
- Proposals Voted: Three proposals were presented to stockholders and all were approved.
Details of Proposals and Voting Results
1. Election of Class II Directors
The stockholders elected the following director to serve as a Class II Director until the 2029 annual meeting or until her successor is duly elected and qualified:
- Susan Mahony, Ph.D., MBA
Voting Results:
- Votes For: 29,892,131
- Votes Withheld: 4,815,060
- Broker Non-Votes: (Not specified for this director in the summary, but these are typically not counted as votes for or against.)
Investor Note: The re-election of Dr. Mahony, with a strong majority, signals continued board stability and support for the current strategic direction.
2. Ratification of Appointment of Deloitte & Touche LLP as Independent Auditor
Stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 43,278,147
- Votes Against: 0
- Abstentions: (Not specified)
- Broker Non-Votes: (Not specified)
Investor Note: Unanimous approval of Deloitte & Touche LLP as the independent auditor demonstrates confidence in the company’s financial oversight and reporting integrity.
3. Advisory Vote on Executive Compensation (“Say-on-Pay”)
The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
Investor Note: Approval of the Say-on-Pay proposal reflects investor alignment with current executive compensation practices, which may indicate satisfaction with management’s performance and the company’s strategic execution.
Other Notable Information
- Emerging Growth Company Status: The Company is no longer classified as an “emerging growth company” under SEC rules. This may impact reporting requirements and is material for investors tracking regulatory status changes.
- Common Stock Information: The Company’s common stock, par value \$0.0001 per share, is listed on the Nasdaq Global Market under the trading symbol AXSM.
Potential Shareholder Impact
What Matters for Investors:
- The overwhelming support for all proposals, especially the strong backing for both the board and executive compensation, suggests broad shareholder approval of Axsome’s management and strategic direction. This stability is generally viewed positively by the market.
- The ratification of a reputable auditor like Deloitte & Touche LLP should bolster investor confidence regarding the quality of financial controls and transparency.
- The company’s transition out of emerging growth company status could have minor implications for compliance costs and disclosure, but is generally an expected evolution for a maturing Nasdaq-listed biotech.
Conclusion
There were no unexpected or controversial items at the 2026 annual meeting. All proposals were approved by large majorities, providing a vote of confidence in Axsome’s leadership and direction. There were no new announcements that would be considered immediately price-sensitive or likely to significantly move the share price in the short term. However, the strong support for management and the board may help sustain positive investor sentiment.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research or consult with a qualified financial advisor before making investment decisions.
